Multi-omics profiling reveals sphingolipid metabolism reprogramming of tumor-conditioned MDSCs in cervical cancer - Report - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Comprehensive Omics Analysis Uncovers Alterations in Sphingolipid Metabolism of Tumor-Influenced MDSCs in Cervical Cancer

  • By

  • Qiuwen Mai

  • Chudan Chi

  • Xiaojun Wang

  • Yili Chen

  • Qiaojian Zou

  • Qianrun Chen

  • Feitianzhi Zeng

  • Mengxun Wei

  • Yanfei Chen

  • Aiting Wang

  • Yan Liao

  • Yuzhou Xiao

  • Xinjie Li

  • Qing Yan

  • Liping Zhan

  • Hongsuo Wei

  • Xu Jing

  • Qiqiao Du

  • Junxiu Liu

  • September 18, 2026

Share

Clinical Report: Comprehensive Omics Analysis of MDSCs in Cervical Cancer

Overview

This study reveals significant alterations in sphingolipid metabolism in tumor-influenced myeloid-derived suppressor cells (MDSCs) in cervical cancer.

Background

Cervical cancer is a leading cause of mortality among women globally, with the tumor microenvironment playing a crucial role in its progression and therapeutic response. Myeloid-derived suppressor cells (MDSCs) are key components of this microenvironment, known for their immunosuppressive functions that contribute to tumor growth and metastasis.

Data Highlights

No numerical or trial data presented in the source material.

Key Findings

  • MDSCs are significantly expanded in cervical cancer patients and correlate with tumor burden.
  • Alterations in lipid metabolism, particularly sphingolipid metabolism, were observed in tumor-conditioned MDSCs.
  • The Kng1–sphingosine 1-phosphate network was identified as a key protein–metabolite interaction in MDSCs.
  • Metabolic reprogramming is crucial for MDSC survival and function within the tumor microenvironment.

Clinical Implications

The findings suggest that targeting sphingolipid metabolism in MDSCs may provide a novel therapeutic strategy in cervical cancer. Further investigation into the metabolic pathways of MDSCs could enhance our understanding of their role in immune evasion.

Conclusion

This comprehensive analysis underscores the importance of MDSCs in cervical cancer and their metabolic adaptations within the tumor microenvironment. Targeting these alterations may offer new avenues for therapeutic intervention.

Related Resources & Content

  1. Author(s)/Org, Source, Year -- Title
  2. Frontiers in Immunology — Increased Sialylation of Bone Marrow Mesenchymal Stromal Cells Facilitates Immune Remodeling via Macrophage Polarization in Patients with Multiple Myeloma
  3. Blood Cancer Journal — Integrative Omics Analysis Uncovers Changes in the Immune Microenvironment in Multiple Myeloma and Its Precursor Conditions
  4. Brain — Inhibition of CCL2 Alongside PD-1 and P-Selectin Immunomodulators Reduces Brain Metastasis in Breast Cancer
  5. Gastric Cancer — Lineage-Specific Changes in Tumor-Associated Macrophages Promote Immune Evasion in Ascitic Tumor Cells of Gastric Cancer with Peritoneal Metastasis
  6. Cervical Cancer, Version 2.2026, NCCN Clinical Practice Guidelines In Oncology.
  7. https://ejgo.org/Synapse/Data/PDFData/1114JGO/jgo-37-e29.pdf
  8. Myeloid-derived suppressor cells in cancer: biology, regulatory networks and theranostic prospects | Signal Transduction and Targeted Therapy

Original Source(s)

Multi-omics profiling reveals sphingolipid metabolism reprogramming of tumor-conditioned MDSCs in cervical cancer

  • by Qiuwen Mai, Chudan Chi, Xiaojun Wang, Yili Chen, Qiaojian Zou, Qianrun Chen, Feitianzhi Zeng, Mengxun Wei, Yanfei Chen, Aiting Wang, Yan Liao, Yuzhou Xiao, Xinjie Li, Qing Yan, Liping Zhan, Hongsuo Wei, Xu Jing, Qiqiao Du, Junxiu Liu

  • September 18, 2026

Related Content

Current status and future directions of AI in prostate cancer detection on MRI: a special report from the ESUR prostate MRI working group authors

Correction to: HLA Class II molecule HLA-DRA identifies immuno-hot tumors and predicts the therapeutic response to anti-PD-1 immunotherapy in NSCLC

Personalized Cancer Vaccine Linked to Three-Year Disease-Free Survival in Head and Neck Cancer

All 16 patients who received TG4050 after standard treatment remained disease-free, compared with 13 of 16 patients in the control group

  • September 16, 2026

  • 2 min